CJC / IPA Blend
A dual-receptor GH-axis research blend combining GHRH-R and GHS-R1a signaling
- Fulfillment Origin
- us
CJC / IPA Blend combines Modified GRF (1-29), commonly marketed as CJC-1295 without DAC, with Ipamorelin. The two components act through separate pituitary receptor systems: GHRH-R and GHS-R1a. Both pathways converge on endogenous growth-hormone release and downstream IGF-1 signaling. Direct peer-reviewed studies of the exact co-lyophilized blend are limited, so component-level findings should not be presented as validated blend outcomes.
Two-peptide research blend · configured total 10 mg
- Formula
- Modified GRF (1-29): C152H252N44O42; Ipamorelin: C38H49N9O5
- Molecular weight
- Modified GRF (1-29): approximately 3367.9 Da; Ipamorelin: approximately 711.9 Da
- Form
- Lyophilized powder blend
- CAS / ID
- Modified GRF (1-29): 863288-34-0; Ipamorelin: 170851-70-4
Independently tested. Verifiably pure.
Every batch of CJC / IPA Blend is reviewed against its independent laboratory documentation before fulfillment.
- HPLC Purity AnalysisReported purity: Component- and lot-specific purity — see COA
- Mass SpectrometryComponent identity by mass spectrometry — see lot COA
- Heavy Metals ScreeningLot-specific result — see COA
- Endotoxins (LPS)Lot-specific result — see COA
- Sterility TestingLot-specific result — see COA
- Net Peptide ContentTotal and component content — see COA
- HPLC Purity
- Component- and lot-specific purity — see COA
- Identity
- Component identity by mass spectrometry — see lot COA
- Endotoxin (LAL)
- Lot-specific result — see COA
- Lab
- Independent third-party laboratory
Not for human or veterinary use. For in-vitro laboratory research only. This product is not intended to diagnose, treat, cure, or prevent any disease.
Two upstream signals. One shared GH-axis endpoint.
Modified GRF (1-29) and Ipamorelin are separate peptide identities. The first engages the growth-hormone-releasing-hormone receptor, while the second engages the ghrelin receptor GHS-R1a.
Modified GRF (1-29) · 5 mg
A 29-residue, no-DAC GHRH analog studied for GHRH-receptor activation and cAMP/PKA-linked pituitary signaling.
Ipamorelin · 5 mg
A synthetic pentapeptide growth-hormone secretagogue investigated for selective GHS-R1a activation and PLC/IP3-linked signaling.
Dual receptor activation
The blend provides an experimental format for studying two distinct receptor pathways that converge on endogenous GH release.
The CJC / IPA dual-pathway model.
The animated diagram presents two independent peptide nodes and two receptor pathways converging at the pituitary GH node. It does not depict the blend as one molecule.
Published component-level research observations.
These summaries refer to Modified GRF/CJC-1295-related and Ipamorelin literature. They do not establish clinical efficacy or validated synergy for the exact blend.
GHRH-receptor signaling
Modified GRF analogs are studied for pituitary GHRH-receptor activation and cAMP-mediated growth-hormone release.
Selective ghrelin-receptor signaling
Ipamorelin was characterized as a selective growth-hormone secretagogue in foundational pharmacology research.
Convergent endocrine research
The blend supports experimental comparison of two upstream receptor mechanisms converging on GH and IGF-1 endpoints.
Visual percentages indicate dossier emphasis, not efficacy, potency or clinical outcomes.
Two receptor pathways converge.
The dynamic signaling map keeps the two second-messenger systems separate before joining them at endogenous GH release.
GHRH-R to cAMP / PKA
Modified GRF (1-29) engages GHRH receptors on pituitary somatotrophs and is associated with cAMP/PKA signaling.
GHS-R1a to PLC / IP3
Ipamorelin engages GHS-R1a through a distinct ghrelin-receptor signaling pathway involving PLC/IP3.
Shared downstream endocrine endpoint
Both upstream pathways can be studied through pituitary GH release and downstream IGF-1 signaling.
How the two components differ.
The table distinguishes receptor target, molecular class and signaling route. It does not compare therapeutic effectiveness.
Modified GRF (1-29)
A no-DAC GHRH analog with a 29-residue peptide sequence.
Ipamorelin
A selective pentapeptide secretagogue targeting GHS-R1a.
Endogenous GH release
Both components act upstream of GH rather than serving as exogenous GH.
| Component | Molecular class | Primary receptor | Second-messenger context |
|---|---|---|---|
| Modified GRF (1-29) | 29-residue GHRH analog | GHRH-R | cAMP / PKA |
| Ipamorelin | Pentapeptide GHS | GHS-R1a | PLC / IP3 |
Dual-receptor profile visualized.
The bars illustrate the two upstream receptor systems and their shared downstream endpoint.
A blend has no single half-life.
Modified GRF (1-29) and Ipamorelin have distinct exposure and degradation behavior. A single clearance curve for the whole blend would be scientifically misleading.
Short-acting Modified GRF
This dossier is configured for the no-DAC Modified GRF (1-29) identity, not albumin-binding CJC-1295 with DAC.
Separate molecular behavior
Ipamorelin must be evaluated as its own analytical and pharmacokinetic entity.
No universal clearance profile
Formulation-, route- and model-specific data are required before publishing a combined duration claim.
Percentages reflect nominal mass composition only.
Full specification.
Nominal composition is separated from lot-specific analytical results. Final published values must match the actual supplier specification and Certificate of Analysis.
CJC / IPA Blend
Two-component lyophilized GH-axis research blend.
5 mg + 5 mg
Modified GRF (1-29) + Ipamorelin; total 10 mg.
Approximately 3367.9 Da
Formula C152H252N44O42; CAS 863288-34-0; no DAC.
Approximately 711.9 Da
Formula C38H49N9O5; CAS 170851-70-4.
Lyophilized powder
Appearance and fill characteristics must be confirmed per lot.
See lot COA
Confirm both component identities, purity, content and applicable contaminant testing.
From dual receptor activation to downstream signaling.
This is a mechanistic research sequence, not a treatment or dosing timeline.
GHRH-R activation
Modified GRF (1-29) engages the pituitary GHRH receptor.
GHS-R1a activation
Ipamorelin engages the ghrelin receptor through a separate secretagogue pathway.
Pituitary GH release
Both pathways converge on endogenous growth-hormone secretion.
Downstream IGF-1 signaling
GH-dependent research endpoints may include downstream IGF-1 and pulse-pattern measurements.
Handle both peptides as sensitive research materials.
Storage, preparation and working stability must follow supplier-validated documentation rather than generic website claims.
Cold, dry and protected
Minimize moisture, repeated temperature cycling and direct light. Follow the validated condition stated for the supplied lot.
Time and matrix matter
Stability depends on solvent, concentration, container, pH, temperature and handling conditions.
Validate both identities
Prepared-sample stability should be evaluated for both Modified GRF and Ipamorelin.
- Record the lotLink each experiment to the vial batch and corresponding COA.
- Use validated preparation instructionsDo not infer preparation conditions solely from another product page.
- Limit freeze-thaw cyclesPrepare appropriate aliquots when supported by the experimental protocol.
- Document hold timeRecord preparation time, temperature and elapsed time before analysis.
For in-vitro laboratory research only. Not for human or veterinary use.
Component literature library.
The literature supports the scientific context of the individual components and related receptor systems. It does not validate the exact blend as a clinical product.
Foundational pharmacology characterizing Ipamorelin as a selective growth-hormone secretagogue.
View primary source →Clinical research on long-acting CJC-1295 with DAC. Included for GHRH-analog context; it should not be treated as direct no-DAC blend evidence.
View primary source →Research context for ghrelin-receptor signaling and growth-hormone-secretagogue biology.
View primary source →Review of GH secretagogue mechanisms and interaction with endogenous GHRH pathways.
View primary source →References.
Independent literature supporting the component-level scientific context used in this dossier.
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.Open source ↗
- Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.Open source ↗
- Raun K et al. Pharmacological characterization of Ipamorelin and selective GH-secretagogue signaling.Open source ↗
- General GHRH and ghrelin-receptor literature supporting dual-pathway GH-axis research.Open source ↗
Related products
CJC-1295 Whit DAC
IGF-1 LR3
Ipamorelin
Sermorelin
TESA / IPA Blend
